Maximal mouth opening (interincisal distance) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
1 finding from 1 review
Goel 2015 (3-arm: intralesional betamethasone vs lycopene vs placebo, 90 per arm): appeared to show increased interincisal distance in both intervention groups vs placebo, but only between-group differences with no…
1 study · 180 participants
GRADE not reported
Maximal mouth opening (interincisal distance) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
It is very uncertain whether tongue depressor stretches (physiotherapy) changes maximal mouth opening (interincisal distance) compared with intralesional steroid plus hyaluronidase injections (very low certainty).
1 finding from 1 review
Maximal mouth opening (interincisal distance) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
1 finding from 1 review
Singh 2010 (hydrocortisone+hyaluronidase 50 vs triamcinolone+hyaluronidase 50): mouth opening reported categorically (trismus) rather than as continuous data, precluding quantitative analysis; authors found no…
1 study · 100 participants
GRADE not reported
Maximal mouth opening (interincisal distance) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
1 finding from 1 review
Sudarshan 2012 (topical aloe vera 10 vs antioxidant capsules 10): reported improvement in interincisal distance but no baseline data, so change could not be determined; excluded from meta-analysis.
1 study · 20 participants
GRADE not reported
Maximal mouth opening (interincisal distance) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
Pentoxifylline may leads to lower maximal mouth opening (interincisal distance) compared with spirulina (low certainty).
1 finding from 1 review
Maximal mouth opening (interincisal distance) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
It is very uncertain whether hydrocortisone plus hyaluronidase (intralesional) changes maximal mouth opening (interincisal distance) compared with placebo or no active treatment (very low certainty).
1 finding from 1 review
Maximal mouth opening (interincisal distance) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
It is very uncertain whether intralesional triamcinolone changes maximal mouth opening (interincisal distance) compared with intralesional salvianolic acid B (very low certainty).
1 finding from 1 review
Rate of maxillary molar intrusion for correction of anterior open bite · Adolescents and adults with malocclusion undergoing fixed orthodontic appliance treatment
1 finding from 1 review
Two studies (62 participants), not pooled. Abellan 2021: no significant difference in molar intrusion at 3 months (1.25 vs 1.72 mm) or 6 months (1.09 vs 1.28 mm), nor rate per month. Hasan 2022: increased intrusion…
2 studies · 62 participants
GRADE not reported
Awareness of prolapse: Laparoscopic versus open · women with apical vaginal prolapse
Sacral colpopexy: laparoscopic showed no clear difference in awareness of prolapse: Laparoscopic versus open compared with alternative approach (low certainty).
1 finding from 1 review
Toxicity – neutropenia grade 3–5 · people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
Platinum doublet may leads to higher toxicity – neutropenia grade 3–5 compared with non‐platinum therapy (low certainty).
1 finding from 1 review
Toxicity – thrombocytopenia grade 3–5 · people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
Platinum doublet may leads to higher toxicity – thrombocytopenia grade 3–5 compared with non‐platinum therapy (low certainty).
1 finding from 1 review
Neutropenia · people with non‐transfusion‐dependent β‐thalassaemia
It is very uncertain whether one dose or dose regimen of a foetal haemoglobin inducer changes neutropenia (WBC < 1 × 103/μL, ANC < 0.5 × 103/μL) compared with another dose or dose regimen of the same foetal haemoglobin inducer (very low certainty).
1 finding from 1 review
Thrombocytopenia (platelet count < 50 × 103/μL) · people with non‐transfusion‐dependent β‐thalassaemia
It is very uncertain whether one dose or dose regimen of a foetal haemoglobin inducer changes thrombocytopenia (platelet count < 50 × 103/μL) compared with another dose or dose regimen of the same foetal haemoglobin inducer (very low certainty).
1 finding from 1 review
Febrile neutropenia (grade III/IV) · early triple‐negative breast cancer
Platinum‐containing chemotherapy showed no clear difference in febrile neutropenia (grade III/IV) compared with chemotherapy without platinum (moderate certainty).
1 finding from 1 review
Open‐label use of systemic corticosteroids · preterm infants
It is very uncertain whether inhaled corticosteroids changes open‐label use of systemic corticosteroids compared with placebo (very low certainty).
1 finding from 1 review
Neutropenia · women with recurrent epithelial ovarian cancer
175 mg/m2 paclitaxel showed no clear difference in neutropenia compared with 250 mg/m2 paclitaxel (low certainty).
1 finding from 1 review
Neutropenia ‐ not reported · women with recurrent epithelial ovarian cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Neutropenia · women with recurrent epithelial ovarian cancer
Weekly paclitaxel may leads to lower neutropenia compared with three‐weekly paclitaxel (low certainty).
1 finding from 1 review
Scar severity ‐ Helium‐Neon (He‐Ne) laser plus decamethyltetrasiloxane, polydimethylsiloxane and cyclopentasiloxane cream versus decamethyltetrasiloxane, polydimethylsiloxane and cyclopentasiloxane cream ‐ Vancouver Scar scale (VSS) (higher scores... · participants with hypertrophic and keloid scars
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Grade 3 to 4 neutropenia · first‐line treatment of ovarian cancer
Weekly paclitaxel plus carboplatin showed no clear difference in haematological adverse event: Grade 3/4 neutropenia compared with tri‐weekly paclitaxel plus carboplatin (moderate certainty).
1 finding from 1 review